Needham & Company reiterates a 'Buy' on Martek Biosciences Corporation (Nasdaq: MATK), price target $32.

Needham analyst says, "MATK turned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE